Alessandra Cianflone

Dr. Alessandra Cianflone


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ACAlessandra Cianflone
Alessandra Cianflone
LCLuigi Coppola
Luigi Coppola
PPPasquale Primo
Pasquale Primo
GMGiovanna Maisto
Giovanna Maisto
FMFiorenza Mastrodonato
Fiorenza Mastrodonato
Peppino MirabelliPeppino Mirabelli
Peppino Mirabelli
Laboratory tests play a crucial role in the diagnostic process for both adults and children. Indeed, they are essential for evaluating health status and formulating effective treatment strategies in the presence of disease. However, in the case of pediatrics, distinct physiological and developmental features of children should be taken into account when compared to adults. Consequently, it is necessary to consider some factors, such as reference intervals that vary significantly at different stages of development due to sexual development, cerebral maturation, and biological and environmental influences; furthermore, it must be considered that extremely small volumes of biological samples are often necessary to obtain accurate laboratory results. Finally, timely test results are critical, especially for pediatric conditions that are treatable when diagnosed early. This review article provides a comprehensive overview of advanced diagnostic technologies, including rapid next-generation sequencing and complex point-of-care testing, within the context of pediatric laboratory medicine. Special attention is given to diagnostic tools that support neonatal and pediatric intensive care units, with a focus on how innovative technologies, particularly those utilizing artificial intelligence algorithms, can accelerate diagnostic workflows.

10 June 2026 in Genes
Verified
Journal Article
Open access
PDF file
PPPasquale Primo
Pasquale Primo
FCFrancesco Cecere
Francesco Cecere
ACAlessandra Cianflone
Alessandra Cianflone
FMFiorenza Mastrodonato
Fiorenza Mastrodonato
GMGiovanna Maisto
Giovanna Maisto
Peppino MirabelliPeppino Mirabelli
Peppino Mirabelli
Background/Objectives: Acute lymphoblastic leukaemia (ALL) is a biologically heterogeneous disease in which transcriptional dysregulation contributes to disease onset and progression. Despite survival rates exceeding 90% in high-income countries, relapsed and high-risk cases remain a major clinical challenge, highlighting the need for improved molecular stratification, namely the classification of patients based on genetic and transcriptomic features associated with prognosis, therapeutic response, and disease biology, as well as for the identification of novel therapeutic targets. Methods: We performed an integrative cross-platform analysis to investigate the expression and potential relevance of three candidate genes: PXDN, TCF4, and TSPAN7 in ALL. Gene expression was interrogated across the MILE microarray cohort and the St. Jude Cloud PeCan paediatric RNA-sequencing dataset. Results: Differential expression analyses consistently showed significant upregulation of TCF4 and PXDN in B-cell ALL (B-ALL) across both platforms (adjusted p < 0.001), while TSPAN7 displayed higher expression in T-cell ALL (T-ALL) and variable upregulation in B-ALL. These findings were supported by preliminary validation using quantitative PCR in paediatric B-ALL samples. To explore potential functional associations, we performed gene regulatory network inference using scGraphVerse, identifying differentially expressed genes putatively linked to PXDN, TCF4, and TSPAN7. Structural modelling using AlphaFold suggested candidate protein–protein interaction interfaces for a subset of these genes, although these predictions require experimental validation. Functional enrichment analysis indicated an over-representation of developmental pathways associated with PXDN- and TCF4-related networks, whereas TSPAN7-associated genes were enriched in processes linked to neuronal lineage development. Conclusions: Collectively, our results identify, for the first time, PXDN, TCF4 and TSPAN7 as differentially expressed genes in ALL and highlight the usefulness of integrative transcriptomic analyses across independent datasets. While limited by small-scale experimental validation and reliance on computational predictions, this study provides a framework for prioritising candidate genes and generates testable hypotheses regarding their potential involvement in leukaemia-associated molecular pathways.

1 July 2026 in Clinical Epigenetics
Verified
Journal Article
Open access
ACAlessandra Cianflone
Alessandra Cianflone
FCFrancesco Cecere
Francesco Cecere
LCLuigi Coppola
Luigi Coppola
FCFabiana Cacace
Fabiana Cacace
PMPeppino Mirabelli
Peppino Mirabelli
FTFrancesco Paolo Tambaro
Francesco Paolo Tambaro
Background: Epigenetic dysregulation is a key therapeutic target in pediatric hematologic malignancies resistant to conventional chemotherapy, where allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option. In this setting, hypomethylating agents (HMAs), such as azacitidine (AZA) and decitabine (DAC), are increasingly used as pre-transplant bridging strategies to reduce disease burden and enhance treatment sensitivity. Their integration with HSCT may improve pre-transplant remission rates, prolong complete remission, and increase the likelihood of durable disease control and cure. However, evidence in pediatric patients remains limited. Here, we performed a systematic review and pooled analysis to evaluate the efficacy of pre-HSCT epigenetic therapy in pediatric hematologic malignancies. Results: A pooled analysis of seven studies of 87 pediatric patients including 51 Myelodysplastic Syndromes (MDS) and 36 Juvenile Myelomonocytic Leukemia (JMML) treated with DAC or AZA prior to HSCT was performed. Statistical analyses used chi-squared or Fisher’s exact tests for categorical variables and non-parametric tests for continuous variables, with correction for multiple comparisons. In MDS, Complete remission (CR) was achieved in 64.7% of patients and strongly associated with DAC, translating into improved post-HSCT survival compared to PD (84.2% vs. 42.8%). In JMML, partial remission (PR) and progressive disease (PD) predominated (47.2% and 41.7%, respectively), while CR was rare (11.1%); response was not associated with HMA type or genetic features, although older age correlated with PD. Comparative analysis confirmed superior responses in MDS (higher CR and SD) versus JMML, which showed higher PR and PD rates. PTPN11 mutations were significantly associated with multiple clinical variables, including treatment response. Conclusions: Pre-transplant HMA therapy shows variable efficacy in pediatric myeloid malignancies. DAC induces rapid, deep responses in MDS, improving post-HSCT survival. JMML responds less, yet post-transplant survival remains favorable. Higher HMA responsiveness in MDS likely reflects predominant epigenetic dysregulation, whereas JMML is mainly driven by aberrant RAS/MAPK pathway activation. These results emphasize that pre-transplant strategies should be tailored to the specific biological and clinical context of each disease. However, their impact relative to upfront HSCT or conventional chemotherapy remains to be definitively determined.